TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A narrative review published in 2026 argues that clinicians should better identify neuropathic pain among people with persistent pain after intensive care. It proposes studying neuromodulation for selected patients, but says there is not enough direct evidence to establish these treatments for ICU survivors.
A narrative review published November 5, 2026, argues that chronic neuropathic pain may be an underrecognized problem for some intensive care unit survivors and proposes research into neuromodulation for carefully selected patients. The authors stress that post-ICU pain has multiple possible causes and that better diagnosis must come before applying these approaches; direct evidence supporting neuromodulation in this population remains insufficient.
The review, titled “Neuromodulation for Refractory Neuropathic Pain Following Critical Illness: A Narrative Review and Phenotype-Based Clinical Framework,” was written by Suresh Srinivasan, Kiran Khurshid, Uzam Hussain, Joseph Pathakamuri and Mohanraj Palani Selvam. The authors say recovery after critical illness can involve persistent pain alongside weakness, mobility limitations, sleep disruption, cognitive difficulties and psychological distress.
The review cites a 2026 meta-analysis estimating chronic pain incidence at about 47% three months after critical illness, 29% at six months and 31% at 12 months. Those figures concern chronic pain overall, not neuropathic pain specifically. In a separate prospective multicenter cohort of 814 patients, nearly 48% reported significant persistent pain three months after ICU admission; among those reporting pain, about 9% screened positive for neuropathic symptoms. The authors caution that study populations, definitions and follow-up periods differ.
Neuropathic pain may follow nerve injury, including critical illness polyneuropathy, while other survivors’ pain may arise from muscle injury, immobility, surgery or deconditioning. The review describes peripheral nerve stimulation, dorsal root ganglion stimulation and spinal cord stimulation as potential research options for selected pain patterns. It does not establish that these procedures work for ICU survivors.
Why Pain Type Changes Treatment
Distinguishing nerve pain from other post-ICU pain matters because symptoms alone do not establish a diagnosis, and treatment needs to match the source of disability. The authors note that critical illness polyneuropathy can affect sensory and motor nerves, but critical illness myopathy primarily affects muscle. Weakness by itself, they warn, should not be treated as proof of neuropathic pain.
That distinction can affect recovery planning. Rehabilitation, physical therapy, psychological support, sleep measures and individualized medication remain part of care, according to the review. Some medicines used for neuropathic pain may be difficult for certain recovering patients to tolerate, especially when renal impairment, cognitive problems, dizziness, sedation or respiratory vulnerability are present. The authors argue that persistent symptoms that limit rehabilitation warrant assessment rather than automatic medication escalation.
The proposed neuromodulation options have different targets, which makes patient selection important. Peripheral nerve stimulation could be studied for focal nerve injuries; dorsal root ganglion stimulation for selected regional syndromes; and spinal cord stimulation for some bilateral or multisegmental pain patterns. These are proposed research directions, not treatment recommendations proven for this population.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Coway Mighty AP-1512HH(W) Air Purifier, White
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Evidence From Other Pain Conditions
The review situates its proposal within existing neuromodulation research, while cautioning against assuming results will carry over to ICU survivors. It cites the ACCURATE trial, which found higher three-month treatment success with dorsal root ganglion stimulation than conventional spinal cord stimulation among patients with lower-extremity complex regional pain syndrome or causalgia. It also cites the SENZA-PDN trial, which reported substantial pain relief with 10-kHz spinal cord stimulation in patients with refractory painful diabetic neuropathy.
Those studies involved different patient groups and diagnoses. The review authors say their results provide a rationale for further study, but cannot establish efficacy after critical illness. The review’s central proposal is a phenotype-based framework: first characterize the pain and its likely mechanism, then investigate whether a particular stimulation approach is appropriate for that pattern.
“We need to identify neuropathic pain earlier, understand its underlying mechanisms, and investigate treatment strategies beyond conventional pharmacotherapy when symptoms remain disabling.”
— Suresh Srinivasan, Kiran Khurshid, Uzam Hussain, Joseph Pathakamuri and Mohanraj Palani Selvam, review authors
What ICU-Specific Evidence Lacks
The review does not establish how many ICU survivors have confirmed chronic neuropathic pain. The cited prevalence estimates measure chronic pain broadly or screening-positive symptoms, and the authors note that study methods and follow-up periods vary. A positive screening result is not the same as a definitive diagnosis.
It is also unclear whether peripheral nerve stimulation, dorsal root ganglion stimulation or spinal cord stimulation would be safe and effective for particular ICU-related pain conditions. Evidence from complex regional pain syndrome and diabetic neuropathy cannot settle that question. The review is a narrative synthesis and proposed framework; the source does not report a clinical trial testing these procedures in ICU survivors.
Diagnosis Before Stimulation Trials
The next step described by the authors is more precise evaluation of persistent pain after critical illness, including determining whether symptoms are neuropathic and identifying their likely source. They call for investigation of targeted treatments when symptoms remain disabling despite appropriate conventional care.
Further studies would need to define which patients might benefit, match interventions to pain patterns and assess outcomes and risks in the ICU-survivor population. Until direct evidence is available, the review supports careful diagnosis and research, not assuming neuromodulation is an established option for post-ICU neuropathic pain.
Key Questions
How common is chronic pain after critical illness?
The review cites a 2026 meta-analysis estimating chronic pain incidence at about 47% at three months, 29% at six months and 31% at 12 months. These are estimates for chronic pain overall, not specifically neuropathic pain.
Does persistent pain after an ICU stay mean nerve damage?
No. Pain can have several causes, including muscle injury, surgery, immobility and deconditioning. The authors say weakness alone does not establish neuropathic pain; clinical evaluation is needed to identify the likely cause.
Are stimulation procedures proven for ICU survivors?
The review says direct clinical evidence is insufficient to establish peripheral nerve, dorsal root ganglion or spinal cord stimulation for this population. Trials in other pain conditions do not prove these treatments work after critical illness.
What care does the review describe for recovery?
The authors describe rehabilitation, physical therapy, psychological support, sleep measures and individualized medication management as important parts of recovery. Treatment should be tailored to the person’s symptoms and health circumstances.
Source: medpagetoday.com
